Ignite Creation Date:
2025-12-24 @ 7:00 PM
Ignite Modification Date:
2026-01-06 @ 9:22 AM
Study NCT ID:
NCT02070757
Status:
COMPLETED
Last Update Posted:
2020-05-05
First Post:
2014-02-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-09-02
Start Date Type:
ACTUAL
Primary Completion Date:
2018-05-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-06-06
Completion Date Type:
ACTUAL
First Submit Date:
2014-02-19
First Submit QC Date:
None
Study First Post Date:
2014-02-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-05-07
Results First Submit QC Date:
None
Results First Post Date:
2019-05-31
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-04-23
Last Update Post Date:
2020-05-05
Last Update Post Date Type:
ACTUAL